BiotechTube

CAL02 Low-dose + CAL02 High-dose + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pneumonia

Conditions

Pneumonia, Pneumococcal Infections

Trial Timeline

Mar 21, 2016 → Feb 20, 2018

NCT ID
NCT02583373

About CAL02 Low-dose + CAL02 High-dose + Placebo

CAL02 Low-dose + CAL02 High-dose + Placebo is a phase 1 stage product being developed by Combioxin for Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT02583373. Target conditions include Pneumonia, Pneumococcal Infections.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02583373Phase 1Completed

Competing Products

20 competing products in Pneumonia

See all competitors
ProductCompanyStageHype Score
tacrolimusAstellas PharmaPre-clinical
23
Cefiderocol + Best Available TherapyShionogiPhase 3
77
Cefiderocol + Meropenem + LinezolidShionogiPhase 3
77
Cefiderocol + Standard of Care AntibioticShionogiPhase 1
33
ONO-5046Na + ONO-5046NaOno PharmaceuticalPhase 2
52
doripenemJohnson & JohnsonApproved
85
levofloxacin; imipenem/cilastitinJohnson & JohnsonPhase 3
77
levofloxacinJohnson & JohnsonPhase 3
77
levofloxacinJohnson & JohnsonPhase 2/3
65
LevofloxacinJohnson & JohnsonPhase 3
77
doripenemJohnson & JohnsonPhase 3
77
doripenemJohnson & JohnsonPhase 3
77
Doripenem + Imipenem-Cilastatin + PlaceboJohnson & JohnsonPhase 3
77
Imipenem/cilastatin + Imipenem/cilastatin + Doripenem + DoripenemJohnson & JohnsonPhase 2
52
HRS-8427 + MeropenemJiangsu Hengrui MedicinePhase 2
52
Ceftazidime-avibactamAbbViePhase 1
33
Ticagrelor + PlaceboAstraZenecaPhase 2
52
Tedizolid phosphate + LinezolidMerckPhase 3
77
Ceftolozane/Tazobactam + Piperacillin/TazobactamMerckPhase 3
77
IMI/REL FDC + PIP/TAZ FDC + LinezolidMerckPhase 3
77